[CAS NO. 17318-31-9] SQ22536

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [17318-31-9]

Catalog

SLK-S8283

Brand

Selleck

CAS

17318-31-9

DESCRIPTION [17318-31-9]

Overview

MDL	MFCD00210216
Molecular Weight	205.22
Molecular Formula	C9H11N5O
SMILES	NC1=C2C(N(C=N2)C3CCCO3)=NC=N1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	4.8728 mL	24.3641 mL	48.7282 mL
5 mM	0.9746 mL	4.8728 mL	9.7456 mL
10 mM	0.4873 mL	2.4364 mL	4.8728 mL
50 mM	0.0975 mL	0.4873 mL	0.9746 mL

Description

SQ22536 (9-(tetrahydrofuran-2-yl)-9h-purin-6-amine) is an inhibitor of with an of 1.4 μM. It can inhibit PGE1-stimulated increases in cAMP levels in intact human platelets.

Targets

Adenylyl cyclase ^[1]

In vitro

SQ22536(250 µmol/L) attenuates the inhibitory effect of adenosine against ADP-induced platelet aggregation from 8±5 to 57±5%, respectively (p<0.001). SQ22536 also attenuates an increase of intraplatelet levels of cAMP by adenosine from 29±2 to 9±1 pmol/108 platelets (p<0.05). It has no effect on the platelet antiaggregant activity of inosine (1 to 4 mmol/L) and ADP-induced platelet aggregation.

In vivo

SQ22536 abolishes the renal protective effects of liraglutide in KK/Ta-Akita mice. the amelioration of glomerular histopathological damage by liraglutide is eliminated in KK/Ta-Akita mice treated with liraglutide in combination with SQ22536. Renal cAMP does not increase after treatment with SQ22536. In a word, the beneficial actions of liraglutide for treatment of nephropathy are inhibited by the adenylate cyclase inhibitor SQ22536.

References

[1] Gao Y, et al. Eur J Pharmacol. 2002, 436(3):227-33.
[2] Cao J, et al. Mol Pharmacol. 2006, 69(3):998-1006.
[3] Xia L, et al. J Endocrinol. 2015, 224(3):225-34.
[4] Fuentes E, et al. PLoS One. 2014, 9(11):e112741.
[5] Fujita H, et al. Kidney Int. 2014, 85(3):579-89.

Synonyms

9H-Purin-6-amine, 9-(tetrahydro-2-furanyl)-

Adenine, 9-(tetrahydro-2-furyl)-

9-(Tetrahydro-2-furanyl)-9H-purin-6-amine

9-(Tetrahydro-2-furyl)adenine

SQ 22536

Tetrahydrofuryl-9-adenine

NSC 53339